Trial · NCT04950127
Adverse event totals18
The totals the trial posted for each group.
1 to 18 of 18
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Part A: Placebo | 0 | 118 |
| Total, all-cause mortality | Part A: Linerixibat 40 Milligrams (mg) | 0 | 119 |
| Total, all-cause mortality | Part B: Placebo in Part A and Part B | 0 | 53 |
| Total, all-cause mortality | Part B: Placebo in Part A and Linerixibat 40 mg in Part B | 0 | 52 |
| Total, all-cause mortality | Part B: Linerixibat 40 mg in Part A and Placebo in Part B | 0 | 46 |
| Total, all-cause mortality | Part B: Linerixibat 40 mg in Part A and Part B | 0 | 45 |
| Total, other adverse events | Part A: Placebo | 54 | 118 |
| Total, other adverse events | Part A: Linerixibat 40 Milligrams (mg) | 96 | 119 |
| Total, other adverse events | Part B: Placebo in Part A and Part B | 5 | 53 |
| Total, other adverse events | Part B: Placebo in Part A and Linerixibat 40 mg in Part B | 16 | 52 |
| Total, other adverse events | Part B: Linerixibat 40 mg in Part A and Placebo in Part B | 3 | 46 |
| Total, other adverse events | Part B: Linerixibat 40 mg in Part A and Part B | 7 | 45 |
| Total, serious adverse events | Part A: Placebo | 4 | 118 |
| Total, serious adverse events | Part A: Linerixibat 40 Milligrams (mg) | 14 | 119 |
| Total, serious adverse events | Part B: Placebo in Part A and Part B | 0 | 53 |
| Total, serious adverse events | Part B: Placebo in Part A and Linerixibat 40 mg in Part B | 0 | 52 |
| Total, serious adverse events | Part B: Linerixibat 40 mg in Part A and Placebo in Part B | 2 | 46 |
| Total, serious adverse events | Part B: Linerixibat 40 mg in Part A and Part B | 0 | 45 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04950127/event-totals